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ABSTRACT  
X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disorder of the 
nervous system characterized by axonopathy in spinal cords and/or cerebral 
demyelination, adrenal insufficiency and accumulation of very long-chain fatty acids 
(VLCFA) in plasma and tissues. The disease is caused by malfunction of the ABCD1 
gene, which encodes a peroxisomal transporter of VLCFA or VLCFA-CoA. In the 
mouse, ABCD1 loss causes late onset axonal degeneration in the spinal cord, associated 
with locomotor disability resembling the most common phenotype in patients, 
adrenomyeloneuropathy. We have formerly shown that an excess of the VLCFA C26:0 
induces oxidative damage, which underlies the axonal degeneration exhibited by the 
Abcd1- mice. In the present study, we sought to investigate the noxious effects of C26:0 
on mitochondria function. Our data indicate that in X-ALD patients’ fibroblasts, excess 
of C26:0 generates mtDNA oxidation and specifically impairs oxidative 
phosphorylation triggering mitochondrial ROS production from electron transport chain 
complexes. This correlates with impaired Complex V phosphorylative activity, as 
visualized by high-resolution respirometry on spinal cord slices of Abcd1- mice. Further, 
we identified a marked oxidation of key OXPHOS system subunits in Abcd1- mouse 
spinal cords at presymptomatic stages. Altogether, our results illustrate some of the 
mechanistic intricacies by which the excess of a fatty acid targeted to peroxisomes, 
activates a deleterious process of oxidative damage to mitochondria, leading to a 
multifaceted dysfunction of this organelle. These findings may be of relevance for 
patient management while unveiling novel therapeutic targets for X-ALD. 
 
Keywords: X-linked adrenoleukodystrophy, mitochondrial respiration; axonal 
degeneration; oxidative stress; very long-chain fatty acids  
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INTRODUCTION 
X-linked adrenoleukodystrophy (X-ALD: McKusick no. 300100) is a rare 
neurodegenerative disorder characterised by an inflammatory cerebral demyelination, or 
a progressive axonopathy in the spinal cord, causing spastic paraparesis (1-3). With a 
minimum incidence of 1 in 17,000 males, X-ALD is the most frequent inherited 
leukodystrophy and peroxisomal disorder. It is caused by mutations in the ABCD1 
gene, which encodes for an ATP-binding cassette transporter located in the peroxisomal 
membrane. The function of the ABCD1 protein is key in the import of very long-chain 
fatty acids (VLCFA, C≥22:0) and VLCFA-CoA esters into the peroxisome for 
degradation (4, 5). As a consequence, the loss of the ABCD1 transporter results in the 
accumulation of VLCFA in most patients’ organs, fibroblasts and plasma due to a lack 
of substrate for the VLCFA -oxidation in peroxisomes (6-8). The main accumulated 
VLCFA is the hexacosanoic acid, or C26:0 that serves as a pathognomonic biomarker 
for the biochemical diagnosis of the disease.  
The classical inactivation of the ABCD1 transporter in the mouse elicits a late-
onset neurodegenerative phenotype with axonal damage in the spinal cord. The 
inflammatory demyelination is absent in the brain of this mouse model, which rather 
resembles the most frequent X-ALD phenotype, the adult adrenomyeloneuropathy or 
AMN (9, 10). Signs of oxidative stress have been found in X-ALD patients’ blood 
samples and post-mortem brains (11-13). In this regard, we have formerly delivered 
evidences for an early, at presymptomatic stages occurring oxidative stress, concomitant 
with a bioenergetic dysfunction characterized by depleted ATP and NADH levels (14-
16). Indeed, a treatment with a mixture of antioxidants reverses oxidative damage, 
metabolic failure and axonal degeneration in this model, providing proof of concept on 
the pivotal contribution of oxidative damage to disease pathogenesis (17-19). 
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The combination of a disturbance in energy homeostasis with oxidative stress, 
involving the mitochondria as a major player, is a common phenomenon in the 
physiopathogenesis of age-related neurodegenerative diseases, such as Parkinson’s 
disease (PD), Huntington’s disease (HD), Alzheimer’s disease (AD) or amyotrophic 
lateral sclerosis (20, 21). Of note, we and others have previously described 
ultrastructural abnormalities in mitochondria from neurons of Abcd1- and Abcd2-/- 
mouse spinal cords (22) and Abcd1- adrenocortical cells (23), consistent with 
observations in AMN patients (24, 25), and peroxisomal-deficient Zellweger patients 
(26) and Pex5-/- mice (27).  
In the present study, we set out to investigate mitochondrial function in the most 
common peroxisomal disease. We reveal a defective activity of oxidative 
phosphorylation (OXPHOS) in fibroblasts of X-ALD patients and in spinal cord of 
Abcd1- mice at presymptomatic stages, using high-resolution respirometry. This is 
accompanied by the oxidation of the catalytic subunits of the mitochondrial Complex 
V/H+-ATP synthase, a bottleneck of oxidative phosphorylation. Furthermore, taking 
advantage of the cellular model provided by patients’ fibroblasts, we show that excess 
of C26:0 specifically impairs oxidative phosphorylation and generates mitochondrial 
ROS at complex I and II of the electron transport chain (ETC) in these X-ALD cells.  
 
RESULTS 
Increased oxidation of mitochondrial proteins in spinal cords of Abcd1- mice 
Based on a functional genomics analysis, we recently reported several altered 
mitochondrial pathways, including energetic metabolism, in 12-month-old Abcd1- 
spinal cords (28). Also, we described oxidative lesions in proteins of Abcd1- spinal 
cords, and identified specific oxidation targets, including several proteins involved in 
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glycolysis and the tricarboxylic acid (TCA) cycle. This was accompanied by decreased 
levels of ATP and NADH, and several metabolites of TCA cycle (18). Most recently, 
we uncovered oxidation of a mitochondrial permeability transition component, the 
cyclophilin D (15). These experiments were performed using homogenates of whole 
spinal cord tissue. Because of the intrinsic limitations of 2D proteomic experiments, 
including the difficulty of detecting proteins in low abundance, we thought of repeating 
the 2D experiments on mitochondria-enriched fractions. Then, using mass spectrometry, 
we identified the following proteins as markedly oxidised in Abcd1- samples: - and -
ATP synthase (Complex V of the OXPHOS), cytochrome b-c1 complex subunit 2 
(Complex III of the OXPHOS), aspartate aminotransferase (AST) and the voltage 
dependent anion channel (VDAC) (Fig. 1A, 1B). In addition, the TCA cycle enzymes 
malate dehydrogenase (MDH) and aconitase (ACO2), the latter of which was previously 
detected in whole spinal cord extracts (18), showed increased levels of oxidation. These 
results suggest an increase in oxidative damage in Abcd1- spinal cords that affects key 
enzymes involved in mitochondrial energetic metabolism and confirmed that 
mitochondrial proteins are direct targets of oxidative lesions in spinal cords of the X-
ALD mouse model. 
 
Oxidative phosphorylation is impaired in the spinal cord of Abcd1- mice  
Several reports indicate that the oxidation of enzymes involved in energy 
metabolism may result in a decrease in their activity (21). To investigate whether 
OXPHOS activity is altered in X-ALD mice nervous tissue, we carried out high-
resolution respirometry experiments using Oroboros technology (29). Because a 
previous study reported no impairment in respiratory efficacy when working with 
purified mitochondria from muscle of an X-ALD mouse model (30), we sought to focus 
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on the spinal cord, the main disease target organ, and applied an ex-vivo approach using 
freshly sectioned slices from presymptomatic 12-month-old Abcd1- mice and control 
littermates.  
Maximum oxygen consumption rates of spinal cords were assessed in the 
presence of the mitochondrial uncoupler carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), showing no significant differences in the 
activity of complexes of the ETC between both phenotypes (Fig. 2). Inhibition of 
Complex III of the ETC with antimycin A almost completely abolished oxygen 
consumption in spinal cords of both WT and Abcd1- mice (Fig. 2), strongly supporting 
the specificity of the oxygen consumption assay in permeabilized spinal cord slices. 
However, we noted that oxygen consumption after the addition of ADP, ADP + 
succinate or ADP + succinate + rotenone was significantly diminished in Abcd1- mice 
when compared to controls (Fig. 2). These results evidence that the activity of the H+-
ATP synthase is reduced in the spinal cords of Abcd1- mice, while activity of the 
respiration complexes remains conserved.  
 
C26:0 excess induces inefficient oxidative phosphorylation in X-ALD patients’ 
fibroblasts 
To investigate whether an excess of C26:0 could be responsible for the observed 
mitochondrial dysfunction, we studied X-ALD patients’ fibroblasts using the Seahorse 
Extracellular flux analyzer (XL24). This device is designed to measure oxygen 
consumption rates in adherent cells, allowing evaluation of cellular bioenergetics such 
as Oligomycin Sensitive Respiration (OSR), which is indicative of the activity of the 
mitochondrial H+-ATP synthase, and the Maximum Respiratory Capacity (MRC) after 
 at U
niversidad A
utonom
a de M
adrid. Biblioteca de Econom
icas on June 10, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
8 
 
the addition of the uncoupler 2,4-dinitrophenol  (DNP), which is indicative of maximum 
activity of the respiratory chain (31, 32). 
Fibroblasts grown in glucose produce their ATP principally by glycolysis, 
largely by-passing the mitochondria. However, when the same cells are grown in 
glucose-free medium containing galactose, they are forced to raise the activity of 
OXPHOS system to produce ATP (33, 34). Consistent with this, OSR of both control 
and X-ALD fibroblasts determined in galactose media, were significantly increased 
when compared to the rates assayed in glucose media (Fig. 3A). Of note, control and X-
ALD fibroblasts showed the same OSR when grown in glucose or galactose media (Fig. 
3A), indicating a conserved activity of OXPHOS in fibroblasts of X-ALD patients 
under these conditions. Moreover, no differences were observed in the normalized 
maximum respiratory rates between control and X-ALD fibroblasts when grown in 
glucose or galactose media (Fig. 3B), indicating normal activity of the respiratory chain.  
We next investigated the effect of excess of C26:0 upon OSR capacity. The OSR 
of control fibroblasts was not affected in both glucose and galactose media (Fig. 3A). 
Likewise, the normalized maximum respiratory rate was not affected by incubation with 
C26:0 (Fig. 3B). However, C26:0-treated X-ALD fibroblasts in both glucose and 
galactose conditions showed a diminished activity of oxidative phosphorylation (Fig. 
3A), supporting that C26:0 excess may interfere with this specific mitochondrial 
activity in the patients’ fibroblasts. The negative effect of C26:0 was also noted in the 
maximum respiratory rate in X-ALD fibroblasts when grown in galactose (Fig. 3B), 
unveiling a mitochondrial OXPHOS disruption induced by C26:0, which can be 
ascribed to a lower ATP synthase activity rather than lower respiratory complex 
activities. This is consistent with the results obtained on spinal cord slices. 
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We have previously observed that X-ALD fibroblasts, but not control cells, 
accumulate oxidative lesions to proteins in the presence of C26:0 (14). This may 
suggest that OSR diminution in X-ALD fibroblasts reflects C26:0-induced severe 
oxidation or impairment of OXPHOS subunits provoking the drop in oxidative 
phosphorylation activity, as revealed in the spinal cord of Abcd1- mice.  
 
The uncoupling of the oxidative phosphorylation or the inhibition of complexes I 
and II blocks free radical production  
Using the probe carboxy-H2DCFDA (dichlorofluorescein), which detects 
reactive oxygen species (ROS) of any intracellular origin, we formerly reported that an 
excess of C26:0 produced oxidative lesions in proteins and generated ROS (14). 
However the origin of these ROS is still unknown. Because mitochondria constitute the 
main source of ROS in many pathological conditions (35), and our results indicated 
impaired oxidative phosphorylation, we sought to investigate whether also in X-ALD, 
mitochondria would represent a main source of ROS. We thus used the fluorescent dyes 
DHE (dihydroethidium) and MitoSOX (DHE covalently bonded to hexyl 
triphenylphosphonium cation), which measure intracellular and intra-mitochondrial 
ROS levels, respectively (36). The levels of ROS induced by C26:0, detected using 
either DHE or MitoSOX probes, were similar (Fig. 4A). This indicates that 
mitochondria are major sources of ROS when fibroblasts are loaded with excess of 
C26:0. Similar results using the MitoSOX probe were observed by Baarine et al. after 
incubating a murine transformed oligodendrocyte cell line (518N) with C26:0 and other 
VLCFAs (37).  
As to the molecular sources of these ROS, we hypothesized that the ROS 
induced by C26:0 could be derived from the ETC because C26:0 somehow disrupts 
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oxidative phosphorylation in X-ALD fibroblasts. We thus employed different 
compounds that disrupt the oxidative phosphorylation in control and X-ALD 
fibroblasts. We observed that C26:0-mediated ROS generation was prevented when the 
ETC flow was uncoupled by the application of carboxy-carbonyl cyanide m-
chlorophenylhydrazone (CCCP) (Fig. 4B). In addition, when Complex V was inhibited 
by oligomycin, we also observed the prevention of C26:0-mediated ROS production 
(Fig. 4C). These results highlight the mitochondrial OXPHOS system as the main 
molecular source of ROS induced by C26:0 and support the role played by the activity 
of the H+-ATP synthase as a ROS-signalling cellular device (38). Of note, two subunits 
of this enzyme are markedly oxidized in spinal cords of the mouse model of X-ALD 
(Fig. 1A, 1B). 
We furthermore investigated whether the inhibition of ETC complex I by 
rotenone and complex II by thenoyltrifluoroacetone (TTFA) (39) could lead to an 
alteration in the process of C26:0-mediated ROS generation. Indeed, the joint inhibition 
of both complexes I and II prevented C26:0-induced ROS (Fig. 4D). In contrast, no 
effects on C26:0-mediated ROS production were observed following complex III 
inhibition by antimycin (Supplementary Fig. 1A), or after the inhibition of NADPH 
oxidases by apocynin (Supplementary Fig. 1B) or the inhibition of cytochrome P450 by 
metyrapone (Supplementary Fig. 1C). Altogether, these results suggest that the C26:0-
mediated ROS generation is produced by the ETC, with evidence that complexes I and 
II may most likely constitute the main sources of ROS upon C26:0 excess in this 
cellular system. These results are in agreement with the reduced OSR observed in X-
ALD fibroblasts in presence of C26:0 overload, which suggests that C26:0 may hamper 
by an unknown mechanism the correct electron transport, facilitating electron leakage, 
and thus decreasing the phosphorylative respiration in these cells (Fig. 3A). 
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Mitochondrial DNA is oxidised in cerebral AMN brain samples and in human 
fibroblasts after C26:0 exposure  
 Compared to nuclear DNA, mitochondrial DNA is more sensitive to mutations 
caused by oxidative stress because of certain factors that include a lack of protective 
histones and the close proximity of the mitochondrial genome to the inner 
mitochondrial membrane where ROS are produced (40). To investigate whether an 
excess of C26:0 was able to generate mtDNA damage, we measured mtDNA oxidation 
levels by means of a Q-PCR approach. This is based on the fact that PCR efficiency is 
directly correlated to DNA oxidation levels (41), i.e. unlike that of a small DNA 
fragment (100 bp), the PCR efficiency of large DNA fragments (1 kb) is diminished by 
oxidation as deletions occur. Thus, the difference in PCR efficiency between a small 
and a large DNA fragment in the same locus allows us to measure the number of 
oxidised bases/kb. We applied this technique to samples of brain white matter of human 
adrenomyeloneuropathy patients, and detected increased mtDNA oxidation ratios in the 
affected white matter zones, which show active demyelinising plaques (Fig 5A). To 
investigate whether excess of C26:0 could be responsible for this effect, we used human 
fibroblasts and exposed the cells to excess of C26:0, showing that both control and X-
ALD cells had increased oxidation rates under these conditions (Fig. 5B). Taken 
together, our data support the hypothesis that an excess of C26:0 triggers a vicious cycle 
of mitochondrial dysfunction that may constitute the initial steps in the 
neurodegenerative cascade in this disease.  
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DISCUSSION 
Oxidative stress has been classically considered to be a common event in the 
neurodegenerative cascade in a variety of conditions (20, 21). Moreover mitochondria, 
and in particular the ETC, have been identified as main sources of ROS in many 
neurodegenerative diseases (35). The leakage of electrons from the electron transport 
chain located on the inner mitochondrial membrane is the source of superoxide O2·-, 
which then produces H2O2 by dismutation (42). ROS are extremely reactive molecules 
that oxidise nearby macromolecules in the absence of the antioxidant defence system 
(43). This oxidation can induce mutations in DNA and structural and functional 
modifications to proteins and lipids, increasing a pathological cascade of molecular 
damage that, if not neutralized, may lead to cellular demise.  
A main conclusion of this study is that an excess of C26:0 disrupts the 
mitochondrial oxidative phosphorylation and induces the generation of free radicals at 
the ETC, in particular when oxido-reduction reactions take place in both complexes I 
and II, at least in human fibroblasts. This in turn may lead to ETC malfunctioning and 
defective phosphorylative respiration evidenced in vitro in fibroblasts and ex-vivo using 
spinal cord slices of presymptomatic X-ALD mice. Thus, we propose that an 
oxidatively damaged and functionally impaired OXPHOS system may be at the sources 
of the neurodegenerative cascade in X-ALD. This hypothesis is consistent with previous 
findings studying neurodegenerative models. HD patients show a decrease in the 
activity of complex I in skeletal muscle, and complexes II/III and IV in the brain (44). 
The activity of complex I in the substantia nigra and in the frontal cortex of PD patients 
is also reduced. In addition, complex IV activity is decreased in the hippocampus of AD 
patients (45). Moreover, it has been demonstrated that both the inhibition of complex I 
by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) and complex II by 3-
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nitropropionic acid (3-NP) in rodents leads to PD and HD, respectively (46, 47). Our 
data appear to be in contrast with previous research in the field showing that respiration 
in isolated mitochondria from the muscle of an Abcd1- mouse was normal (30). As the 
muscle is not an organ primarily affected in the disease, one possible explanation could 
be that mitochondria susceptibility to VLCFA excess may vary among tissues and cell 
types, as the functions of these organelles may show a certain degree of heterogeneity 
and super-specialization among populations to adapt to specific demands and 
physiological functions.  
Moreover, as a logical consequence of excessive mitochondrial ROS production, 
we also identified an increase in oxidised mtDNA and mitochondrial proteins of TCA 
cycle and OXPHOS in X-ALD nervous tissues. Of note, the oxidised molecules 
observed in X-ALD have already been identified in several neurodegenerative disorders 
including mtDNA in the brains of patients with AD (48) and  HD (49); VDAC1 and - 
and -ATP synthase in AD (21, 50); aconitase in AD and HD (21); aspartate 
aminotransferase in a HD mouse model (51); and cytochrome b-c1 oxidation in the 
frontal cerebral cortex of advanced AD (43). This may be one underlying reason for the 
bioenergetic deficiency common to all these neurodegenerative diseases, and provide 
the rationale for exchange of therapeutic strategies among these pathologies (17).  
The precise molecular mechanisms that may drive the noxious interaction of 
C26:0 with mitochondria membranes and thus, the excessive mitochondria-derived 
ROS production in the context of X-ALD remains obscure at present. It is worth noting 
that the accumulation of fatty acids causes the mitochondria dysfunction underlying 
both common and rare conditions, such as type 2 diabetes or Refsum disease (52-54). 
Because it has been shown that C26:0 can interact with a phospholipid bilayer 
membrane provoking a perturbation of bilayer organisation (55-57), it is conceivable 
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that an excess of C26:0, perhaps substituting other fatty acid species, namely 
polyunsaturated or monounsaturated fatty acids at the lateral chains of membrane 
phospholipids, could interfere with mitochondrial membrane structure and fluidity, 
which would disturb the proper physical interaction of OXPHOS subunits and facilitate 
electron leakage. These ROS would then attack fatty acid anions and produce lipid 
peroxides, which are highly reactive and could lead to oxidative damage to DNA, RNA 
and enzymes of the membrane such as the ATP synthase, or the matrix, which in turn 
would lead to structural damage to mitochondria. As a consequence, the inner 
membrane potential would decrease along with the ETC inefficiency and ROS 
production reported here (Fig.6). The elucidation of the more precise molecular 
mechanism should be addressed in future studies. 
 Taken together, our results indicate that an excess of C26:0 induces 
mitochondrial dysfunction in X-ALD by producing:  i) mitochondrial ROS, ii) 
mitochondrial oxidative damage to DNA and proteins, and iii) inefficient oxidative 
phosphorylation (Fig. 6). The mechanism appears to be the excessive generation of 
mitochondrial ROS through the chronic accumulation of C26:0, which irrevocably 
exacerbates mitochondrial dysfunction and leads to cell demise. In summary, our 
present study underscores the critical role of impaired mitochondria respiration and 
bioenergetics in the pathogenesis of X-ALD, which is of great importance for the 
clinical management of X-ALD patients. Furthermore, our results spotlight an oxidative 
phosphorylation impairment early in the physiopathological cascade underlying axonal 
degeneration and thus, pave the road for new therapeutic strategies using new-
generation antioxidants targeted to mitochondria. This may be of relevance for other 
neurodegenerative diseases presenting mitochondrial dysfunction and for metabolic 
conditions caused by the accumulation of very long-chain saturated fatty acids that are 
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potentially toxic to this vital organelle.  
 
MATERIAL AND METHODS  
Material 
The following chemicals were used: 6-carboxy-2’, 7’-
dichlorodihydrofluorescein diacetate, diacetoxymethyl ester (H2DCFDA)(Molecular 
probes); dihydroethidium (DHE) (Molecular Probes) ; MitoSOX (Molecular Probes) ; 
hexacosanoic acid (C26:0)(Sigma) ; CCCP (Sigma) ; FCCP (Sigma) ; oligomycin 
(Sigma) ; antimycin A (Sigma) ; rotenone (Sigma) ; thenoyltrifluoroacetone (TTFA) 
(Sigma) ; apocynin (Sigma) ; metyrapone (Sigma) ; N,N,N',N'-tetramethyl-p-
phenylenediamine (TMPD) (Sigma). 
 
Antibodies  
The following antibodies were used for western blots: anti-DNP: dilution 1/100 
(Invitrogen) as primary antibody and goat anti-rabbit IgG linked to horseradish 
peroxidase, dilution: 1/15000 (P0448, Dako, Glostrup, Denmark) as secondary 
antibody.  
 
Cell Culture and Treatments 
Control and X-ALD human fibroblasts were grown as described (14). Control 
(n=7) and X-ALD human fibroblasts (n=9) were treated in medium containing fetal 
bovine serum (10%) for 24 hours with ethanol as control, C26:0 (50M), or an inhibitor 
with C26:0 (50M). The following battery of inhibitors was used: CCCP (10M), 
oligomycin (8M), rotenone (10nM), TTFA (500M), antimycin A (1M), apocynin 
(ranges from 50 to 300M, higher doses produced cell lethality) metyrapone (ranges 
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from 50 to 500M, higher doses produced cell lethality). Experiments were carried out 
with cells at 80-90% of confluence, which had a number of passages ranging from 12 to 
15.  
 
Mouse breeding  
The generation and genotyping of Abcd1- mice has previously been described (9, 
10, 58). Mice used for experiments were of a pure C57BL/6J background. Males were 
sacrificed and tissues were recovered and conserved at −80°C. All methods employed in 
this study were in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publications No. 85–
23, revised 1996) and with the ethical committee of The Bellvitge Institute of 
Biomedical Research and the government of Catalonia. 
 
Human brain samples   
Brain tissues from cerebral X-linked adrenoleukodystrophy patients and healthy 
male control subjects, age matched, were obtained from the Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland, Baltimore, MD, USA as 
described in (28). Four clinically diagnosed cALD (cerebral childhood ALD) patients 
and five cAMN (cerebral adrenomyeloneuropathy) patients were used. Informed written 
consent was obtained from all patients or their legal representatives and the local ethics 
committee. 
 
Mitochondrial DNA damage 
Mitochondrial DNA oxidation level was quantified by a Q-PCR approach has 
earlier reported (41). 
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Two-dimensional electrophoresis and western blotting 
Redox proteomics for the identification of oxidised proteins in mice spinal cords 
and human fibroblasts were performed as previously described (18).  
 
Mitochondria enrichment 
Fifty mg of fresh spinal cord is homogenized in 1mL of ice-cold sucrose buffer 
(sucrose 0.32M, HEPES 4mM pH7.4 and protease inhibitor cocktail) using a dounce 
with tight pestle and centrifuged 10min at 1000g in a refrigerated microcentrifuge. The 
supernatant (S1a) is kept in ice and the pellet resuspended in 750 l of ice-cold sucrose 
buffer, then centrifuged 10min at 1000g in a refrigerated microcentrifuge. The 
supernatant (S1b) is kept in ice and the pellet resuspended in 750 l of ice-cold sucrose 
buffer, then centrifuged 10min at 1000g in a refrigerated microcentrifuge. The 
supernatant (S1c) is kept in ice and the pellet discarded. S1a, S1b and S1c are 
centrifuged at 16000g for 10min in a refrigerated microcentrifuge. The pellet contains 
the mitochondrial and lysosomal enriched fractions.  
 
Evaluation of intracellular ROS 
Intracellular ROS levels were estimated using different ROS-sensitive 
fluorescent probes (H2DCFDA) excepted when it is specified in the figure legend as 
described (14). H2DCFDA and DHE probes were used to quantify intracellular ROS. 
MitoSOX™ Red (Molecular Probes) was used to quantify intra-mitochondrial ROS. 
Following incubation with 10 M H2DCFDA for 30 min, 5 M DHE for 30 min or 5 
M MitoSox for 10 min, cells were washed twice with PBS and lysed with 1% Triton 
X-100 (10 min, 4ºC). The homogenate was transferred into a 96-well plate for 
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fluorescence detection with a spectrofluorimeter. Wavelength filters used were: exc. 485 
nm, em. 520 nm for H2DCFDA and exc. 530 nm, em. 590 nm for DHE and MitoSOX. 
Fluorescence values were corrected with protein content and results were expressed as 
percentage to control (untreated cells). 
 
Oxygen consumption rate using Seahorse 
Oxygen consumption rate (OCR) in adherent fibroblasts was measured in 
control and X-ALD fibroblasts with a XF24 Extracellular Flux Analyzer (Seahorse 
Bioscience, Billerica, MA, USA). Fibroblasts were cultured in 12 wells of a XF 96-well 
cell culture microplate (Seahorse Bioscience) at a density of 15×103 cells/well in 100 
μL of growth medium (DMEM with pyruvate, 1g/L of glucose and 10% de FBS). After 
3 h, 150 L of growth medium was added and cell were kept at 37 °C and 5 % CO2 
atmosphere. The next day growth medium was replaced with a glucose-free DMEM 
containing 2mM of L-glutamate, 10% of FBS and 1g/L of glucose. C26:0 (50 M) or 
EtOH was added in the medium, and then cells were incubated for 30h at 37 °C in 5% 
CO2 atmosphere. The cells were incubated at 37°C for 60 min to allow media 
temperature and pH to reach equilibrium before the first rate measurement. After an 
OCR baseline measurement, 50 µL of oligomycin and dinitrophenyl (DNP) were 
sequentially added to each well to reach working concentrations of 6 µM and 500 µM 
respectively and changes in the OCR were analyzed. Oligomycin sensitive respiration 
(OSR) values were calculated from the differences between the baseline OCR and the 
OCR after oligomycin inhibition. Data were expressed as pmol of O2 per minute per 
15000 cells. Mitochondrial maximum respiratory capacity values were obtained from 
the ratio between baseline OCR and the OCR after the addition of the uncoupler DNP. 
All determinations were performed in 7 control and 9 X-ALD fibroblasts. 
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High resolution respirometry using Oroboros  
Oxygen flux of sets of 5 permeabilized slices of spinal cord per mouse (n=4 mice per 
genotype) was measured at 37 °C in MiR05 medium (pH 7.4) by high-resolution 
respirometry using the Oroboros® Oxygraph-2k with chamber volumes set at 2 mL and 
at a slow stirring speed (150 rpm) in order to avoid tissue disaggregation. DatLab 
software (Oroboros Instruments, Innsbruck, Austria) was used for data acquisition (2 s 
time intervals) and analysis, which includes calculation of the time derivative of oxygen 
concentration and correction for instrumental background oxygen flux (59). The spinal 
cord slices permeabilization protocol was a modification of a previously published 
method (60). Fresh spinal cords were rinsed with ice-cold normal saline and cut into 
slices with a tissue chopper adjusted to a cut width of 300 mm. About 12-15 slices of 
the lumbar region were collected and transferred quickly into individual wells of a 6-
well tissue culture plate with 2 ml of ice-cold permeabilization medium (in mM: 7.23 
potassium ethylene glycol-bis(b-aminoethyl ether)N,N,N’,N’-tetraacetate (K2 EGTA), 
2.77 CaK2 EGTA, 60 N,N-bis[2-hydroxyethyl]- 2-aminoethanesulfonic acid (BES), 5.69 
MgATP, 20 taurine, 3 K2HPO4 , 0.5 dithiothreitol and 81 potassium methanesulfonate, 
pH 7.1 at 25◦C), rinsed and immediately transferred again into another well with the 
same medium containing 20 μl of saponin stock solution (5 mg/ml; final concentration 
50 μg/ml). Spinal cord slices were shaken by gentle agitation in the cold room (on ice) 
for 30 min. After the 30 min period, all samples are quickly transferred from the 
saponin permeabilization medium into 2 ml of respiration medium (in mM: 7.23 K2 
EGTA, 2.77 CaK2 EGTA, 100 potassium salt of 2-(N-morpholino)ethanesulfonic acid 
(K-MES), 1.38 MgCl2 , 20 taurine, 3 K2HPO4 , 0.5 dithiothreitol, 20 imidazole and 5 
mg/ml bovine serum albumine (BSA), pH 7.1 at 25ºC), and shaken by gentle agitation 
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for 10 min in the cold room (on ice). For evaluation of relative contributions of 
mitochondrial complexes to oxygen consumption, several specific mitochondrial 
poisons and substrates (rotenone, antimycin A, carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) and N,N,N',N'-tetramethyl-p-
phenylenediamine (TMPD)) were used as previously described (59) and calculated as 
steady-state respiratory flux in the time interval between 5 and 10 min after its addition. 
In order to avoid oxygen limitations, all the experiments were performed above 50% 
oxygen saturation. Initially, we measured endogenous respiration in the absence of 
exogenous substrates. We proceeded to sequentially analyse the activities of the ETC 
complexes. First, we added glutamate and malate to increase NADH levels in order to 
measure the complex I non-phosphorylative activity, or state 2. ADP was added to 
quantify the complex I-dependent phosphorylative activity, or state 3. Immediately 
afterwards, we added succinate, which is the substrate for complex II. At this point, the 
level of O2 consumption corresponded to complex I- and II-dependent phosphorylative 
activity. The addition of rotenone inhibits complex I; therefore, O2 consumption 
measured after the addition of rotenone only reflects complex II-dependent 
phosphorylative activity. Then, complex III activity was inhibited with antimycin A, 
and finally Complex IV maximal activity was measured after addition of the non-
physiological substrate N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD). Maximum 
oxygen consumption rates of spinal cords were measured after addition of FCCP. 
Oxygen consumption was normalized by actual protein content in the respirometer 
chambers. 
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Statistical analysis 
Data are given as mean +/- SD. Significant differences were determined by 
Student’s t-test or one-way ANOVA followed by Tukey’s HSD post hoc (* P <0.05, ** 
P<0.01, *** P<0.001) after verifying normality. Statistical analyses were performed 
using SPSS 12.0 program. 
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FIGURE LEGENDS 
Figure 1: Mitochondrial proteins are more markedly oxidised in spinal cords of 
12-month-old Abcd1- mice 
A) 2D-Redox proteomics of mitochondrial enriched fractions of spinal cords of 12-
month-old WT and Abcd1- mice using two-dimensional gel electrophoresis. Oxidised 
proteins were detected using an anti-DNP antibody. Representative blots are shown 
(n=4 samples/genotype). B) List of more markedly oxidised mitochondrial proteins in 
spinal cords of Abcd1- mice detected by anti-DNP antibody and subsequently identified 
by mass spectrometry. Detailed image of identified proteins is shown (n=4 
samples/genotype). 
 
Figure 2: Oxidative phosphorylation is diminished in Abcd1- mouse spinal cords 
Respiration analysis was performed on permeabilized sections of spinal cords of 12-
month-old WT and Abcd1- mice, using an Oxygraph-2k high-resolution respirometer 
(Oroboros). Statistical analysis was performed using Student’s t-test (* P < 0.05; n=4 
animals/genotype). 
 
Figure 3: Oligomycin sensitive respiration (OSR) and mitochondrial maximum 
respiration capacity (MRC) in human fibroblasts using a Seahorse apparatus 
A) OSR analyzed in control and X-ALD fibroblasts cultured in glucose medium or in 
glucose-free medium containing galactose for 30h, and in the presence or absence of 
C26:0. B) Mitochondrial MRC analyzed in control and X-ALD fibroblasts cultured in 
glucose medium and in glucose-free medium containing galactose for 30h, in presence 
or absence of C26:0. Statistical analysis was conducted by ANOVA and Tukey’s HSD 
post hoc (* P < 0.05; ** P < 0.01; *** P < 0.001; n=6/genotype and condition). 
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Figure 4: Mitochondria are the main source of ROS induced by excess of C26:0 in 
human fibroblasts 
A) Intracellular (DHE) and mitochondria ROS levels (MitoSOX) measured in X-ALD 
human fibroblasts after 24h of incubation with C26:0 (20 or 50 M) or EtOH as vehicle. 
The complex III inhibitor Antimycin A (500 M) was used to treat during 4 h as a 
positive control for mitochondrial ROS production. B) ROS levels in control (CTL) and 
X-ALD human fibroblasts treated with the uncoupling agent CCCP. C) ROS levels in 
CTL and X-ALD human fibroblasts treated with complex V inhibitor oligomycin. D) 
ROS levels in CTL and X-ALD human fibroblasts treated with complex I inhibitor 
rotenone together with complex II inhibitor TTFA (thenoyltrifluoroacetone). Statistical 
analysis was conducted by ANOVA and Tukey’s HSD post hoc (* P < 0.05; ** P < 
0.01; n=5/genotype and condition). 
 
Figure 5: Mitochondrial DNA is oxidised in X-ALD patients’ fibroblasts and 
affected white matter brain samples. 
A) mtDNA oxidation quantified by Q-PCR in affected and normal-appearing X-ALD 
white matter. Statistical analysis was performed by ANOVA and Tukey’s HSD post hoc 
(* P <0.05, ** P <0.01; n=9 samples/group). B) mtDNA oxidation quantified by Q-
PCR in CTL and X-ALD human fibroblasts after an incubation of 24h with C26:0 (20 
or 50 M) or EtOH as vehicle. Statistical analysis was conducted by ANOVA and 
Tukey’s HSD post hoc (* P < 0.05; ** P < 0.01; n=5/genotype and condition). 
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Figure 6: Working model of mitochondrial impairment mediated by excess of 
C26:0.   
Our proposed model attempts to shed light on the mechanisms of mitochondrial 
dysfunction in X-ALD, caused by loss of the peroxisomal transporter ABCD1. As 
hexacosanoic acid (C26:0) cannot enter peroxisomes for degradation, it accumulates 
intracellularly (1). This excess of C26:0 may affect the inner mitochondrial membrane 
permeability by unknown mechanisms. As a consequence, this alteration may decrease 
the m (2) and generate a certain extent of electron leakage promoting ROS formation 
(3). These free radicals oxidise mitochondrial proteins of TCA cycle and OXPHOS, 
leading to impaired bioenergetics and respiration, and also oxidise mtDNA, contributing 
to a vicious cycle of mitochondrial dysfunction and ultimately, cell demise.  
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